The synapse as a treatment avenue for Alzheimer's Disease

L Peng, I Bestard-Lorigados, W Song - Molecular psychiatry, 2022 - nature.com
Alzheimer's disease (AD) is a neurodegenerative disorder with devastating symptoms,
including memory impairments and cognitive deficits. Hallmarks of AD pathology are …

Targeting NLRP3 inflammasome for neurodegenerative disorders

J Yao, Z Wang, W Song, Y Zhang - Molecular Psychiatry, 2023 - nature.com
Neuroinflammation is a key pathological feature in neurological diseases, including
Alzheimer's disease (AD). The nucleotide-binding domain leucine-rich repeat-containing …

[HTML][HTML] Innovative therapy for Alzheimer's disease-with focus on biodelivery of NGF

S Mitra, H Behbahani, M Eriksdotter - Frontiers in neuroscience, 2019 - frontiersin.org
Alzheimer's disease (AD) is a progressive neurodegenerative disorder associated with
abnormal protein modification, inflammation and memory impairment. Aggregated amyloid …

[HTML][HTML] Multi-targets: An unconventional drug development strategy for Alzheimer's disease

CX Gong, CL Dai, F Liu, K Iqbal - Frontiers in aging neuroscience, 2022 - frontiersin.org
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that eventually leads
to dementia and death of the patient. Despite the enormous amounts of resources and …

Doxycycline counteracts neuroinflammation restoring memory in Alzheimer's disease mouse models

C Balducci, G Santamaria, P La Vitola, E Brandi… - Neurobiology of …, 2018 - Elsevier
Abstract β-Amyloid oligomers (AβOs) and neuroinflammation are 2 main culprits to
counteract in Alzheimer's disease (AD). Doxycycline (DOXY) is a second generation …

[HTML][HTML] Alzheimer's disease: challenges and a therapeutic opportunity to treat it with a neurotrophic compound

N Baazaoui, K Iqbal - Biomolecules, 2022 - mdpi.com
Alzheimer's disease (AD) is a progressive neurodegenerative disease with an insidious
onset and multifactorial nature. A deficit in neurogenesis and synaptic plasticity are …

The development of peptide-and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies

M Lozupone, V Dibello, R Sardone… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Tauopathies represent clinicopathological entities with increased and abnormal
glial and/or neuronal inclusions of tau, a microtubule-binding protein. Antisense …

[HTML][HTML] Neuroprotective effects of saffron on the late cerebral ischemia injury through inhibiting astrogliosis and glial scar formation in rats

K Zhong, RX Wang, XD Qian, P Yu, XY Zhu… - Biomedicine & …, 2020 - Elsevier
This study is to explore the neuroprotective effects and involved glial scar of saffron (Crocus
sativus L.) on the late cerebral ischemia in rats. Focal cerebral ischemia was induced by …

Tau and Alzheimer's disease: Past, present and future

K Iqbal - Cytoskeleton, 2024 - Wiley Online Library
My journey with tau started when in 1974 for the first time I isolated neurofibrillary tangles of
paired helical filaments (PHFs) from autopsied Alzheimer's disease (AD) brains and …

Recent developments with tau-based drug discovery

K Iqbal, F Liu, CX Gong - Expert Opinion on Drug Discovery, 2018 - Taylor & Francis
Introduction: Alzheimer's disease (AD), which accounts for three fourth of all cases of
dementia, is a major public health problem in modern society and, yet, there is no effective …